What question did this study set out to answer?

This study investigates the protective effects of syringic acid against LPS-induced acute lung injury and its underlying mechanisms.

March 1, 2026American Journal of AI Digital Transformation and Regenerative Pharmacist

Syringic acid attenuates LPS-induced acute lung injury via modulation of the HMGB1/TLR4/NF-κB and Keap1/Nrf2/HO-1 pathways: Mechanistic insights from in vivo and in silico studies

View Full Paper

Ask AI

Bookmark

Authors

In vivo and in silico studies investigate syringic acid's protective effects against lung injury, indicating potential therapeutic benefits.

This study investigates the protective effects of syringic acid against LPS-induced acute lung injury and its underlying mechanisms.
Conducted in vivo experiments using male Sprague-Dawley rats.
Groups were assigned treatments including control and varying doses of syringic acid and LPS.
SA was administered orally for 14 days prior to LPS injection.
Histopathological and biochemical evaluations of lung tissues were performed following LPS administration.
In silico docking analysis assessed SA's interaction with the KEAP1 protein.
LPS exposure caused significant lung injury, marked by pulmonary edema and inflammation.
Syringic acid pretreatment significantly reduced these damaging effects, especially at 80 mg/kg.
SA modulated key signaling pathways by inhibiting HMGB1/TLR4/NF-kappa B and activating Keap1/Nrf2/HO-1.
Reduced expression of oxidative damage markers and apoptosis indicators was observed with SA treatment.

Çınar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

In vivo and in silico studies investigate syringic acid's protective effects against lung injury, indicating potential therapeutic benefits.